MicroSintesis, a Charlottestown, Canada-based life science company focused on developing proprietary microbiome therapies, received a $16.4m minority investment.
Toronto-based Northern Private Capital (NPC), an investment vehicle of CFFI Ventures, a company controlled by John Risley, made the investment.
The funding will be used to scale-up production of the company’s products and build out research capabilities and platform to deliver a new generation of microbiome products dedicated to improving livestock, companion animal, and human health.
Led by Hannah McIver, CEO, MicroSintesis has identified a set of signal molecules that are part of the microbiome’s own communication system and responsible for regulating its bacteria population. Using patented formulations of these molecules, the company has been able to shift bacterial populations in the gut to deliver a new generation of health products for the future.
In 2018, the company launched commercial products for both the companion animal and livestock markets in Canada. Its Ygia brand for cats and dogs is carried in a growing number of veterinary clinics across Canada and its Nuvio brand for pigs and chickens is sold in six provinces across the country.
To date, Microsintesis’ products have been used in over 2 million animals.